Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Calcipotriol (ausschl. Dafo. CRE), ATC D05AX02 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Mon)

Worth a closer look

• § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be charged to the statutory health insurance funds.
• The procedure is not considered to fall within the scope of cartel procurement law due to the lack of a selection decision and the resulting non-discriminatory access for all pharmaceutical companies.
• The contract ends automatically with the entry into force of the exclusive contract for the active substance Calcipotriol (exclusively Darreichungsform CRE), ATC D05AX02, following a formal procurement procedure according to the regulations of Part 4 of the GWB with one or more contracting partners.
• The contract documents are available for download via the online portal www.dtvp.de/center under the link mentioned under 5.1.11.
• The offer is to be submitted in text form as an electronic offer via email to openhouse@dak.de. Submission of the offer by post is not provided for in this procedure.
• Please do not submit the offer via the German Procurement Portal.
• For the observance of the deadline, the complete documents arriving by email are sufficient.
• Later entries are possible at any time.
• To join during the contract period on the 1st or 15th of the following month, the above documents must be with the DAK-Gesundheit by the 5th of the preceding month, regardless of the desired entry.
• The publication is made using the form for open procedures.
• As already clearly stated, this is such a non-exclusive agreement - the notice had to be used for technical reasons as there is no suitable form for approval procedures.